Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : License entities : Bristol-myers squibb company save search
U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
Published: 2023-05-01 (Crawled : 12:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.76%
H: 2.17%
C: 1.66%
reblozyl fda anemia license review treatment ema application
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
Published: 2023-04-20 (Crawled : 11:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.23%
H: 0.16%
C: -0.24%
license cancer treatment agreement
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) ….
Published: 2023-02-28 (Crawled : 16:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.27%
H: 0.2%
C: -1.2%
drug application opdivo license food nivolumab
BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology
Published: 2022-05-12 (Crawled : 13:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.28%
H: 0.34%
C: 0.29%
BBIO | $25.02 -1.73% -1.76% 1.5M
|
Health Technology
|
| O: -13.79%
H: 0.0%
C: 0.0%
bbp-398 license potential
Bristol Myers Squibb Announces New Prescription Drug User Fee Act Goal Date for Reblozyl® (luspatercept-aamt) Supplemental Biologics License Application
Published: 2022-03-25 (Crawled : 13:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 1.21%
H: 0.0%
C: 0.0%
reblozyl application drug license
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb
Published: 2022-02-25 (Crawled : 12:00) - prnewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
BHVN | News 0 d | $38.72 -2.25% -0.28% 970K
|
Health Technology
|
| O: -4.17%
H: 0.0%
C: 0.0%
license phase 3 muscular atrophy
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb’s Supplemental Biologics License Application for Breyanzi
Published: 2022-02-17 (Crawled : 13:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.15%
H: 0.41%
C: -0.16%
fda application drug license food fda acceptance
U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
Published: 2021-12-03 (Crawled : 12:30) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 1.53%
H: 0.0%
C: 0.0%
transfusion application drug license food
Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings
Published: 2021-09-21 (Crawled : 20:00) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.28%
H: 0.26%
C: -0.58%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: 0.3%
H: 0.19%
C: -0.68%
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: -0.25%
H: 1.24%
C: 0.08%
ABEO | News | $3.165 -7.19% -7.74% 2.2M
|
Health Technology
|
| O: -1.65%
H: 4.2%
C: 0.0%
license
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody ProgramAgenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments
Published: 2021-05-18 (Crawled : 12:15) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.06%
H: 0.58%
C: 0.28%
AGEN A | $7.42 14.86% 12.94% 1.3M
|
Health Technology
|
| O: 29.45%
H: 6.64%
C: -6.87%
antibody license milestone
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
Published: 2021-05-18 (Crawled : 12:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.06%
H: 0.58%
C: 0.28%
AGEN A | $7.42 14.86% 12.94% 1.3M
|
Health Technology
|
| O: 29.45%
H: 6.64%
C: -6.87%
antibody license
Bristol Myers Squibb and The Rockefeller University Announce License Agreement for SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19
Published: 2021-02-03 (Crawled : 13:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.11%
H: 0.54%
C: -1.34%
covid treatment antibody license sars-cov-2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.